State of New Jersey Common Pension Fund D acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 197,856 shares of the biotechnology company’s stock, valued at approximately $2,212,000. State of New Jersey Common Pension Fund D owned 0.09% of ADMA Biologics as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Quest Partners LLC bought a new position in ADMA Biologics in the 2nd quarter worth about $29,000. EntryPoint Capital LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at approximately $31,000. Simplicity Wealth LLC bought a new stake in ADMA Biologics during the 1st quarter valued at $68,000. Oxford Asset Management LLP acquired a new position in ADMA Biologics during the 4th quarter worth $83,000. Finally, CWM LLC grew its stake in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
ADMA has been the topic of a number of recent analyst reports. Cantor Fitzgerald lifted their price objective on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. HC Wainwright upped their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Mizuho raised their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $15.50.
View Our Latest Report on ADMA Biologics
Insider Buying and Selling
In related news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the transaction, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the transaction, the chief operating officer now directly owns 449,088 shares in the company, valued at approximately $7,589,587.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock worth $8,224,121 in the last three months. 3.70% of the stock is currently owned by insiders.
ADMA Biologics Price Performance
Shares of NASDAQ ADMA opened at $19.74 on Friday. ADMA Biologics, Inc. has a twelve month low of $3.06 and a twelve month high of $19.92. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average of $15.63 and a two-hundred day moving average of $10.83. The company has a market capitalization of $4.58 billion, a price-to-earnings ratio of -987.00 and a beta of 0.61.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.02) earnings per share. As a group, analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Recommended Stories
Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report).
Receive News & Ratings for ADMA Biologics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ADMA Biologics and related companies with MarketBeat.com’s FREE daily email newsletter.